Key Takeaways:
China's NMPA granted conditional approval to HUTCHMED's fanregratinib (ATLED) for FGFR2-altered intrahepatic cholangiocarcinoma after a 42.5% response rate in a Phase II trial.
"As a major and devastating subtype of primary liver cancer, intrahepatic cholangiocarcinoma carries an immense disease burden with historically limited targeted options," Johnny Cheng, acting chief executive officer and chief financial officer of HUTCHMED, said.
The approval covers adult patients with advanced, metastatic or unresectable ICC harboring FGFR2 fusion or rearrangement who have received prior systemic therapy. In the single-arm, multi-center, open-label Phase II registration cohort of the NCT04353375 trial, presented at the ESMO Gastrointestinal Cancers Congress 2026, an independent review committee assessed an objective response rate of 42.5 percent (95% confidence interval: 30.0 to 53.6 percent). The study also showed a median duration of response of 6.9 months, a disease control rate of 83.9 percent and median progression-free survival of 6.9 months. Median overall survival reached 16.6 months, with a median time to response of 1.4 months.
ICC accounts for 8.2 to 15 percent of primary liver cancers and carries a five-year overall survival rate of about 9 percent, making it the second most common type after hepatocellular carcinoma. Incidence has continued to rise in recent years. Roughly 10 to 15 percent of ICC patients globally harbor FGFR2 fusions or rearrangements, which are believed to drive tumor cell proliferation. HUTCHMED retains all worldwide rights to fanregratinib and plans to commercialize ATLED in China through its existing infrastructure.
The approval is conditional, pending confirmation from the Phase IIIb portion of the trial, which will serve as the confirmatory study. Enrollment for that cohort began in January 2026.
Fanregratinib is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling drives tumor growth, promotes angiogenesis and contributes to resistance to anti-tumor therapies, according to HUTCHMED.
The approval adds to HUTCHMED's China portfolio, which includes ORPATHYS (savolitinib), cleared by the NMPA in July for MET-amplified gastric cancer. The company's first medicine is also approved in the US, Europe and Japan.
The approval gives HUTCHMED a fourth marketed medicine in China and its first in a molecularly defined liver cancer subtype, expanding its oncology portfolio beyond earlier approvals. It also gives the company a foothold in the FGFR2-altered liver cancer segment, where targeted therapies have been scarce, and its established China commercial infrastructure should accelerate the launch. Investors will watch the confirmatory Phase IIIb readout and initial ATLED sales for evidence the drug can convert regulatory momentum into revenue.
This article is for informational purposes only and does not constitute investment advice.
